The combination of strong revenue growth, successful integration of scPharma, and upcoming FDA catalysts in 2026 suggests potential for continued momentum. Traders should monitor the PDUFA decisions for Afrezza pediatrics and Furoscix ReadyFlow as key value inflection points.
MNKD drugs
MNKD drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $3.24entry
- T+1 · 9mo ago +1.23%α +1.69% · $3.28
- T+5 · 9mo ago −12.65%α −11.53% · $2.83
- T+20 · 8mo ago −29.01%α −22.61% · $2.30
- T+60 · 6mo ago +2.16%α −5.59% · $3.31
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MannKind reported strong fourth quarter and full year 2025 financial results, with Q4 revenue up 46% year-over-year to $112 million and full year revenue up 22% to $349 million, driven by the acquisition of scPharma and growth in Afrezza and Furoscix sales. The company also highlighted upcoming FDA catalysts for Afrezza in pediatrics and Furoscix ReadyFlow Autoinjector.
Key Financial Metrics
Key Facts
- Q4 2025 revenue was $111.96 million, a 46% increase from $76.78 million in Q4 2024
- Full year 2025 revenue was $348.97 million, up 22% from $285.50 million in 2024
- Furoscix generated $23.18 million in net sales following the October 2025 acquisition of scPharma
- Afrezza Q4 2025 net sales were $22.88 million, up 25% from Q4 2024
- Company has $176 million in cash, cash equivalents, and investments as of December 31, 2025
- FDA accepted sBLA for Afrezza in pediatrics with PDUFA date of May 29, 2026
- FDA accepted sNDA for Furoscix ReadyFlow Autoinjector with PDUFA date of July 26, 2026
Financial Impact
Revenue growth of $63.46 million year-over-year, driven by acquisition and product sales growth
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Afrezza | $22.9M | +25.0% |
| Furoscix | $23.2M | Not reported |
| Royalties | $33.6M | +24.0% |
Risk Factors
- Net loss of $15.95 million in Q4 2025 despite revenue growth, indicating ongoing profitability challenges
- Significant increase in SG&A expenses (144% YoY) and R&D expenses (148% YoY) could pressure margins
- Dependence on regulatory approvals for future growth, with inherent uncertainty in FDA decisions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-073509 |
| Document: mnkd-20260226.htm | 0001193125-26-073509 |
| Document: 0001193125-26-073509-index-headers.html | 0001193125-26-073509 |
| Document: 0001193125-26-073509-index.html | 0001193125-26-073509 |
| Document: 0001193125-26-073509.txt | 0001193125-26-073509 |
Track record
17 reports on MNKD
7 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
- Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
- Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
- Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
- Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
- Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
- May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers